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Objective: Stage II esophageal carcinomas are a heterogeneous group of 
uncommon malignant tumors that include both node-negative (IIA; T2 NO 
M0 and I'3 NO M0) and node-positive (IIB; T1 N1 M0 and T2 N1 M0) 
carcinomas. The purpose of this study was to evaluate this heterogeneity 
and to identify predictors of improved survival. Results: Ninety-four of 345 
patients undergoing esophageal resection at the Cleveland Clinic Founda- 
tion between 1985 and 1994 had stage II carcinomas; 70 stage IIA (24 I72 NO 
M0 and 46 T3 NO M0) and 24 stage liB (9 T1 N1 M0 and 15 T2 N1 M0). 
Pathologic stage and T and N status were the only identifiable predictors of 
survival. Stage IIA survival was significantly better than stage liB 07 = 
0.01). T2 NO M0 survival was not different from T1 NO M0 survival 07 = 
0.83). T3 NO M0 survival was significantly worse than T1 NO M0 07 = 0.03) 
and intermediate between T2 NO M0 survival 07 = 0.06) and T1 N1 M0 and 
T2 N1 M0 survivals 07 = 0.07). T1 N1 M0 and T2 N1 M0 survival was not 
significantly different from T3 N1 M0 survival 07 = 0.63). Conclusions: (1) 
NI disease is the principal predictor of reduced survival and N1 is 
independent of T. Therefore the distinction between T1 N1 M0, T2 N1 M0, 
and T3 N1 M0 carcinomas i not warranted. (2) NO disease is the principal 
predictor of improved survival but NO is not independent of T. T1 NO M0 
and T2 NO M0 survivals are similar and therefore distinction between these 
subgroups i  not warranted. T3 NO M0 survival is intermediate between T1 
NO M0 and T2 NO M0 carcinomas and between T1 N1 M0, T2 N1 M0, and 
T3 N1 M0 carcinomas. Therefore stratification by T for NO carcinomas i
warranted. (J Thorac Cardiovasc Surg 1996;111:935-40) 
U ntil 1987 staging of esophageal carcinomas was a neglected practice. Most physicians found little 
use for the unwieldy staging systems, because the 
majority of patients had advanced disease, treat- 
ment had little impact on survival, and no clear 
correlation existed between stage and survival. Co- 
incident with the introduction of a new staging 
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system, 1'2 there came significant advances in clinical 
staging technology 3'4 and the recognition of remark- 
able changes in the epidemioiogy of esophageal 
carcinoma, characterized by a dramatic increase in 
the relative prevalence of adenocarcinoma. 5 
Today the stage of an esophageal carcinoma, as 
defined by its anatomic extent, is the best single 
prognosticator available. The present staging system 
is TNM based (Table I). 6 The status of the primary 
tumor (T) is defined by depth of invasion, and the 
status of regional ymph nodes (N) is characterized 
by the absence (NO) or presence (N1) of metastases. 
Distant metastases are either absent (M0) or 
present (M1). These TNM descriptors are grouped 
into stages with a presumed similar behavior and 
prognosis (Table I). 
Unfortunately, the majority of patients with 
esophageal carcinomas till have stage I I I  or IV 
disease when first examined. Recently, the growing 
appreciation of the malignant potential of Barrett's 
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Table I. The staging of esophgeal carcinomas 
T: Primary tumor 
Tis High-grade dysplasia 
T1 Tumor invades the lamina 
propria, muscularis mucosa, 
or submucosa 
T2 Tumor invades the muscu- 
laris propria 
T3 Tumor invades the peri- 
esophageal tissue 
T4 Tumor invades adjacent 
structures 
N: Regional lymph nodes 
NO No regional lymph node me- 
tastases 
N1 Regional lymph node metas- 
tases 
M: Distant metastasis 
M0 No distant metastasis 
M1 Distant metastasis 
Stage 0 
Stage I
Stage IIa 
Stage IIb 
Stage III 
Stage grouping 
Stage IV 
Tis NO M0 
T1 NO M0 
T2 NO M0 
T3 NO M0 
T1 N1 M0 
T2 N1 M0 
T3 N1 M0 
T4 Any N M0 
AnyT AnyN M1 
esophagus and the increasing use of surveillance 
endoscopy have resulted in more frequent diagnoses 
and resections of stage I esophageal carcinomas. 7 
Although the natural histories of stage I and stage 
I I I  carcinomas have been studied, the behavior of 
stage II carcinomas is less well characterized. 
Stage II esophageal carcinomas are a heteroge- 
neous group of uncommon malignant umors that 
include both node-negative (stage I IA; T2 NO M0 
and T3 N0 M0) and node-positive (stage IIB; T1 N1 
M0 and T2 N1 M0) carcinomas. In this study we 
examined the natural history of surgically treated 
and pathologically staged stage II esophageal carci- 
nomas to identify predictors of improved survival 
and to determine if the subgroups comprising this 
stage have similar behaviors and prognoses. 
Patients and methods 
Patient selection. The hospital records of all patients 
who underwent surgical resection of an esophageal carci- 
noma at the Cleveland Clinic Foundation between Sep- 
tember 1985 and October 1994 were retrospectively re- 
viewed. Pathologic TNM stage, age, gender, histologic ell 
type, and the use of adjuvant herapy were recorded for 
patients with pathologic stage I, II, and III (T3 N1 M0) 
carcinomas. Patients with no residual carcinoma after 
induction therapy and resection, stage 0, advanced stage 
III (T4), and stage IV carcinomas were recorded but not 
analyzed. 
Surgical therapy. Esophageal resection, lymphadenec- 
tomy, and reconstruction with the stomach were per- 
formed by three different surgical approaches. Our ap- 
proach to surgical resection is based on clinical staging 
and the location of the primary carcinoma. Patients 
preoperatively believed to have high-grade dysplasia or 
clinical stage I carcinomas (T1 NO M0) of the lower 
thoracic esophagus, as well as patients with advanced 
carcinomas of the lower thoracic esophagus who were not 
candidates for thoracotomy, underwent a transhiatal 
esophagectomy with lymph node sampling. Rarely, these 
resections were completed via a laparotomy alone. Pa- 
tients who were candidates for thoracotomy and were 
believed clinically to have carcinomas more advanced than 
stage I or those patients with midthoracic or upper 
thoracic esophageal carcinomas underwent esophageal 
resection via a left thoracoabdominal approach, or alter- 
natively aright thoracotomy and upper abdominal midline 
laparotomy. A complete lymphadenectomy was per- 
formed in these patients. Patients with cervical esophageal 
carcinomas involving the larynx and pharynx underwent a 
pharyngolaryngoesophagectomy via a transhiatal ap- 
proach. Esophagogastric anastomoses were constructed in
either the neck or chest by either a sutured or stapled 
technique. 
Adjuvant therapy. During this period two induction 
therapy protocols of chemotherapy and chemoradiation 
therapy were offered to selected patients with clinically 
advanced carcinomas, s-l° Postoperative adjuvant radia- 
tion therapy was offered to selected patients with patho- 
logically advanced carcinomas. These treatments were 
recorded for all patients. 
Pathologic analysis. The following standardized surgi- 
cal pathology protocol for esophageal resection specimens 
is used at the Cleveland Clinic Foundation. The resection 
margins, the esophageal body, the gastroesophageal junc- 
tion, and the regional lymph nodes were extensively 
sampled. When gross lesions were identified, multiple 
sections of each lesion including the area of deepest 
penetration of the esophageal wall were evaluated. When 
a gross lesion was not identified, at least ten sections of the 
esophageal body and gastroesophageal junction were 
evaluated. All separately resected lymph nodes and all 
lymph nodes that were grossly identified in the resection 
specimen were evaluated pathologically. When small 
enough, the entire lymph node was submitted, and two 
levels of that node were examined histologically. Larger 
lymph nodes were bisected and two levels of each of the 
two portions of the bisected lymph node were examined. 
Patient follow-up. The minimum follow-up consisted of 
an annual physical examination, chest roentgenogram, 
complete blood count, and serum chemistries. When 
indicated, computed tomographic s anning, esophagogas- 
troduodenoscopy, and endoscopic esophageal u trasonog- 
raphy were performed. All deaths and causes of death 
were recorded. Sites of recurrence were noted. All living 
patients were contacted before data analysis and fol- 
low-up was obtained for all patients. 
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Table II. Patient demographics 
III 
I IIA liB (T3 N1 MO) 
Age (yr) 
Mean (SD) 64 (12) 64 (11) 60 (10.2) 63 (10.6) 
Range 35-78 31-84 36-83 26-84 
Gender (No.) 
Male 32 52 22 113 
Female 2 18 2 19 
Histology (No.) 
Adenocarcinoma 30 41 18 114 
Squamous cell 4 24 5 15 
Large cell 0 1 0 0 
Adenosquamous 0 4 1 3 
Statistical analysis. Categorical factors were summa- 
rized by use of frequencies and percentages and continu- 
ous measures by use of the mean, standard eviation, 
median, and range. Survival time was calculated from the 
date of the operation to the time of death or most recent 
follow-up. The Kaplan-Meier method was used to esti- 
mate survival and the log rank test was used to test for 
differences in survival distributions between subgroups of 
interest. All tests were performed using a 5% significance 
level, with no formal adjustment for multiple testing. 
Results 
A total of 345 patients underwent esophageal 
resection during the 11-year period. Eighty-four 
patients had no residual carcinoma fter induction 
therapy and resection, stage 0, advanced stage III 
(T4), or stage IV carcinomas and are not further 
discussed. One patient had resection of a T0 N1 M0 
carcinoma after adjuvant therapy and has been 
excluded from analysis, because no staging group 
exists for this patient. Thirty-four patients had re- 
section of stage I esophageal carcinomas and 132 
patients had resection of stage III (T3 N1 M0) 
esophageal carcinomas. Ninety-four (27.2%) pa- 
tients had resection of stage II carcinomas. There 
were 70 (20.2%) stage IIA carcinomas: 24 T2 N0 M0 
and 46 T3 NO M0. There were 24 (7.0%) stage IIB 
carcinomas: 9 T1 N1 M0 and 15 T2 N1 M0. Patient 
characteristics are summarized in Table II. 
Seven (7.4%) patients with stage II disease under- 
went transhiatal esophagectomy. A thoracic incision 
was used in 84 (89.4%) patients; 35 had an Ivor 
Lewis approach and 49 had a thoracoabdominal 
approach. Three patients (3.2%) underwent lapa- 
rotomy for esophagogastric resection. Fifty-six 
(59.6%) patients had no adjuvant herapy, and 38 
(40.4%) patients had perioperative adjuvant therapy 
Table III. Adjuvant herapy 
Induction Postoperative 
Chemotherapy 7 0 
Chemoradiation 13 8 
Radiation 0 10 
Total 20 18 
(Table III). Among the patients who received adju- 
vant therapy, there were 25 stage IIA (10 T2 NO M0 
and 15 T3 NO M0) and 13 stage IIB (six T1 N1 M0 
and seven T2 N1 M0) carcinomas. 
Thirty-four (36%) patients were alive at most 
recent follow-up, 28 with stage IIA and six with stage 
IIB disease. One patient with stage IIB disease was 
alive with a distant recurrence in the liver. There 
were 60 (64%) deaths; 42 of these patients had stage 
IIA disease and 18 stage IIB disease. There were 
two (2.2%) deaths within 30 days of operation; both 
patients who died had stage IIA disease. Two addi- 
tional patients died of late complications during the 
initial hospitalization. These four patients account 
for the 4.4% in-hospital mortality (three with stage 
IIA and one with stage IIB disease). Seven (7.5%) 
patients died without evidence of recurrent carci- 
noma, six with stage IIA and one with stage IIB 
disease. Forty-nine (52.1%) patients died of recur- 
rent carcinoma, 33 with stage IIA and 16 with stage 
IIB carcinoma. Locally recurrent carcinoma was 
documented in 23 patients, 15 with stage IIA and 
eight with stage IIB disease. Distant metastases 
were documented in 27 patients (26 have died); 18 
had stage IIA and nine had stage IIB disease. 
Survival differed by stage (Table IV). Survival for 
patients with stage IIA disease was significantly 
better than for those with stage IIB disease (p = 
0.01) (Fig. 1). Survival for patients with stage I 
disease was better than for those with stage IIA 
disease, but the difference was not statistically sig- 
nificant (p = 0.09). Survival for stage IIB was not 
significantly different from that for stage III (T3 N1 
M0) (p = 0.63). 
Survival differed by T and N status (Table IV, Fig. 
2). Survival of patients with T2 NO M0 disease did not 
differ from that of patients with T1 NO M0 disease 
(p = 0.83). Survival of patients with T2 NO M0 disease 
was better than but not statistically different from the 
survival of patients with T3 NO M0 disease (p = 0.06). 
Survival of patients with T3 NO M0 disease was 
statistically significantly worse than that of patients 
with T1 NO M0 disease (p = 0.03). 
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Fig. 1. Stage IIA and stage liB survival. 
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Fig. 2. Stage II TNM subgroup survival. 
Table IV. Survival information by stage and TNM 
subgroups 
Five-year Median survival 
Stage N survival (%) time (too) 
I: T1 NO M0 34 50 56 
I IA  70 33 27 
T2 NO M0 24 50 28 
T3 NO M0 46 26 26 
I IB 24 - -  20 
T1 N1 M0 9 - -  23 
T2 N1 M0 15 - -  20 
III: T3 N1 M0 132 10 13 
Log rank test p values: 
T1 NO M0 versus T2 NO M0 = 0.83. 
T1 N0 M0 versus T3 NO M0 = 0 03. 
T2 NO M0 versus T3 NO M0 - 0.06. 
T3 NO M0 versus I IB= 0.07. 
l ib versus T3 N1 M0 0.63. 
Survival of patients with T1 N1 M0 and T2 N1 M0 
disease did not differ from that of patients with T3 
N1 M0 disease (p = 0.63). Survival for these patients 
with stage IIB disease was worse than, but not 
statistically different from, the survival of patients 
with T3 NO M0 disease (p = 0.07). 
Survival for patients with stage II disease did not 
otherwise differ on the basis of age older than 70 
years (t7 = 0.89), gender (p = 0.25), cell type (p = 
0.77), or adjuvant therapy (p = 0.37). 
Comments 
The purpose of a staging system is to predict 
survival and, if clinically accurate, to direct therapy. 
Staging of esophageal carcinoma, however, remains 
problematic. Previously used staging systems were 
neither accurate nor predictive and consequently 
were not widely used. The 1988 revision of the 
American Joint Committee on Cancer staging sys- 
tem defined both clinical and pathologic stage by 
depth of tumor invasion (T), the absence or pres- 
ence of regional lymph node metastases (N), and the 
absence or presence of distant metastases (M). 6 The 
stage groupings have been arranged to reflect over- 
all prognosis. Patients with stage I carcinomas have 
a good prognosis, whereas those with stages III and 
IV carcinoma have a poor prognosis. Stage II in- 
cludes patients who should have an intermediate 
survival, but the clinical course of this heteroge- 
neous group has not been well characterized. 
Our results suggest that the current classification 
of stage IIA and stage liB carcinomas warrants 
revision. In patients with regional ymph node me- 
tastases (N1) the carcinomas behave similarly re- 
gardless of the depth of tumor invasion (T1, T2, and 
T3). Patients who are free of regional ymph node 
metastases (NO) tended to have a similar survival; 
however, stratification of these patients by depth of 
tumor invasion seems to be warranted. Our series is 
small and a study of larger numbers of these pa- 
tients, both with and without regional ymph node 
metastases, may further clarify these relationships. 
Our previously reported experience with superficial 
esophageal carcinomas suggests than the survivals of 
patients with stage 0 (high-grade dysplasia) and T1 NO 
M0 carcinomas confined to the lamina propria or 
muscularis propria (intramucosal) are similar] In this 
study the survival of patients with T1 NO M0 carcino- 
mas invading the submucosa (submucosal) was signif- 
icantly worse than that of patients with stage 0 and T1 
NO M0 intramucosal carcinomas. A comparison of 
patients with T1 NO M0 submucosal carcinomas and 
patients with T2 NO M0 carcinomas demonstrates a 
similar survival (p = 0.33). 
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Staging is a dynamic process, and it is reasonable 
to expect a staging system to evolve as understand-  
ing of the disease increases. A l though the current 
staging system represents a significant improvement  
over previous systems, our experience with this 
system has led us to suggest a reclassif ication of the 
staging groups on the basis of survival analysis. Tis 
N0 M0 and T1 N0 M0 intramucosal  carcinomas 
have a similar behavior and good prognosis. 7 We 
consider T1 N0 M0 submucosal  and T2 NO M0 
carcinomas to be similar. The trends in survival ead 
us to consider T3 NO M0 carcinomas as a separate 
group. The differentiation of N1 carcinomas by 
depth of tumor  invasion has no clinical relevance, 
and we consider T1 N1 M0, T2 N1 M0, and T3 N1 
M0 carcinomas to have very similar clinical behav- 
iors. Addi t iona l  studies would be important  in con- 
firming these observations. 
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Discuss ion 
Dr. Tom R. DeMeester (Los Angeles, Calif.). I commend 
the program committee for selecting this paper for pre- 
sentation, because the staging of esophageal cancer is 
indeed an area of controversy. Previous efforts to develop 
satisfactory staging criteria have left much to be desired. 
Two efforts of the American Joint Committee on Cancer, 
one in 1983 and another in 1988, provide poor discrimi- 
nation of the stages according to survival. 
Dr. Ellis, in a 1993 publication (J Surg Oncol 1993;52: 
231-5), showed, like Dr. Killinger, that the 5-year survival 
of patients with stage I IA disease was similar to that of 
patients with stage I disease and the survival of patients 
with stage IIB disease was similar to that of patients with 
stage III disease. 
Again like Dr. Killinger, he showed that there was no 
difference between the 5-year survival of patients with T1 
or T2 disease (i.e., invasion of submucosa or muscularis 
propria). Thus two independent institutions and investi- 
gators have come to the same conclusion: the current 
staging system is inadequate. This needs to be corrected 
for two reasons: First, the current inadequate system 
supports the bias of oncologists that cancer of the esoph- 
agus is a systemic disease from the start and the stage of 
the disease has a minimal role in decisions regarding 
therapy; second, the increase in adenocarcinoma of the 
esophagus and its relation to Barrett's esophagus has 
identified patients who are at risk for the development of
carcinoma nd has placed them in surveillance programs. 
This has resulted in the diagnosis of early disease, at a 
point at which staging has important therapeutic mplica- 
tions. 
Reported experience with resection in patients with 
early disease by other authors (Skinner et al., Cancer 
1982;50:2571-5, and Ellis et al., J Surg Oncol 1993;52:231- 
5), like Dr. Killinger's experience, has identified charac- 
teristics of esophageal cancer that are associated with 
improved survival. They are the depth of cancer penetra- 
tion of the esophageal wall and the presence of lymph 
node metastasis. These observations have given rise to the 
W (wall penetration), N (lymph node metastasis), M
(systemic organ metastasis) taging system proposed by 
Skinner and supported by Ellis. It appears that the 
outcome of Dr. Killinger's study is pointing in the same 
direction. 
On the basis of this background, I have the following 
questions. First, other investigators have found a differ- 
ence in survival between tumors that were intramucosal 
(i.e., limited by the muscularis mucosa), intramural (i.e., 
limited by the muscularis propria), and transmural (i.e., 
extending through the esophageal wall. Did you look at 
your data from this perspective? If so, what were your 
findings? 
Dr. Killinger. Our previously published experience with 
superficial esophageal carcinoma showed no survival dif- 
ference between patients with Tis NO M0, intraepithelial 
carcinomas and those with T1 NO M0 carcinomas that did 
not invade beyond the muscularis mucosae, intramucosal 
carcinomas. There was a significant survival advantage for 
these patients with Tis NO M0 and T1 NO M0 intramucosal 
carcinomas compared with those patients with T1 NO M0 
carcinomas that had invaded the submucosa. In the 
present study, we could find no survival difference be- 
tween those patients with T1 NO M0 submucosal tumors 
and those that have invaded into but not beyond the 
muscularis mucosa, T2 NO M0 carcinomas. Survival is 
worse for those patients with carcinomas that have in- 
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vaded beyond the muscularis mucosa but not into adjacent 
structures, T3 NO M0 carcinomas. Stratification by depth 
of tumor invasion, T, for carcinomas with regional lymph 
node metastases, N1, is of no clinical relevance. 
Dr. DeMeester. Second, other investigators have found 
a difference in survival when lymph node metastases were 
present and when present between patients who had fewer 
than five nodes and five or more nodes involved. Did you 
look at your data from this perspective? If so, what was 
your finding? 
Dr. Killinger. We did not quantify the number of lymph 
nodes that were involved in patients with N1 disease. This 
is an area that is presently under investigation both 
prospectively and retrospectively. 
Dr. DeMeester. Third, other investigators have suggested 
that the ratio of involved nodes to the number of total nodes 
removed has prognostic value, with a ratio of one involved to 
five uninvolved being beneficial. Did you look at your data 
from this perspective? If so, what was your finding? 
Dr. Killinger. We did not quantify the ratio of involved 
to total lymph nodes; however, this information is pres- 
ently being studied. 
Dr. DeMeester. I commend you on your efforts to im- 
prove the staging of esophageal carcinoma. You have added 
supporting evidence that there is a need for a change, 
Ideally, with further accurate data collection by you and 
others, a new and usable staging system will emerge. 
Dr. Arthur N. Thomas (San Francisco, Calif.). I have a 
question and a comment regarding Barrett's esophagus 
and surveillance. I recently operated on a man who had 
negative findings i year earlier and had what was thought 
to be a Tl-type lesion. However, as Dr. DeMeester has 
alluded to, he had a single diseased lymph node when the 
tumor was detected a year later. Thus this patient has a 
very early tumor and one involved lymph node. Is this the 
same as T3 disease? 
Dr. Killinger. It is my understanding that this patient 
had a T1 tumor with metastases to regional lymph nodes 
and no evidence of distant metastases. According to the 
present staging criteria, this patient has a T1 N1 M0, stage 
IIB esophageal carcinoma. 
Dr. Thomas. But the end result will be the same as a 
T3? 
Dr. Kininger. Once regional ymph node metastases 
have occurred there is no need to stratify patients by 
depth of tumor invasion. This patient has a poor survival 
outlook because of regional lymph node metastases, re- 
gardless of the depth of tumor invasion. The prognosis i  
worse than that of a patient with a T3 NO M0 carcinoma. 
Dr. John R. Benfield (Sacramento, Calif.). I would like 
to focus on the very vexing problem of local recurrence 
after esophageal resection. I know that was not the main 
thrust of your paper, but I notice that you identified some 
cases and wonder if during your analysis of the data you 
also elaborated some factors that predispose to local 
recurrence. I also wonder whether there are any lessons to 
be learned about preventing this difficult problem. 
Dr. Killinger. The data were not analyzed to determine 
what factors predicted local recurrences. 
Dr. Paul F. Waters (Los Angeles, Calif.). Were you able 
to dissect out the role of adjuvant therapy? I noticed you 
had stratified those patients. Did that have any effect on 
survival at all? 
Dr. Killinger. The survival of patients who received 
adjuvant therapy was not different from the survival of 
those treated with resection alone. It must be remem- 
bered that a significant number of patients receiving 
induction therapy were downstaged before resection. 
Compared with the survival of similar patients with iden- 
tical pretreatment stage, the survival of these downstaged 
patients was much improved over the expected survival for 
their initial clinical stage. 
Dr. Waters. Was there any difference in complication 
rate? 
Dr. Killinger. There was no statistical difference in 
complication rates between those receiving adjuvant ther- 
apy and those undergoing resection alone. 
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